title: The endothelin system in human glioblastoma.
abstract: Endothelin-1 (ET-1) is a powerful mitogenic and/or anti-apoptotic peptide produced by many cancer cells. To evaluate the potential role of the endothelin system in glioblastoma we first determined the cellular distribution of the mRNA and proteins of the components of the endothelin system, preproendothelin-1 (PPET-1), endothelin-converting enzyme-1 (ECE-1), and ET(A) and ET(B) receptors in human glioblastoma tissue and glioblastoma cell lines. PPET-1, ECE-1, and ET(A) receptor were highly expressed in glioblastoma vessels and in some scattered glioblastoma areas whereas ET(B) receptor was mainly found in cancer cells. This suggests that glioblastoma vessels constitute an important source of ET-1 that acts on cancer cells via the ET(B) receptor. Four human glioblastoma cell lines expressed mRNA for all of the components of the ET-1 pathway. Bosentan, a mixed ET(A) and ET(B) receptor antagonist, induced apoptosis in these cell lines in a dose-dependent manner. Apoptosis was potentiated by Fas Ligand (APO-1L, CD95L), a pro-apoptotic peptide, only in LNZ308 cells, corresponding to the known functional Fas expression in these cell lines. LNZ308 cells also expressed the long and short forms of the cellular FLICE/caspase-8 inhibitory protein (FLIP). Bosentan and a protein kinase C inhibitor down-regulated short FLIP in these cells. ET-1 induced transient phosphorylation of extracellular signal-regulated kinase but did not induce long-term thymidine incorporation in LNZ308 glioblastoma cells. These results suggest that, in glioblastoma cells, ET-1, mainly acting via the ET(B) receptor, is a survival/antiapoptotic factor produced by tumor vasculature, but not a proliferation factor, involving protein kinase C and extracellular signal-regulated kinase pathways, and stabilization of the short form of FLIP.
authors.affiliation: INSERM U36, Collège de France, Paris.
authors.forename: G
authors.initials: G
authors.lastname: Egidy
authors.forename: L P
authors.initials: LP
authors.lastname: Eberl
authors.forename: O
authors.initials: O
authors.lastname: Valdenaire
authors.forename: M
authors.initials: M
authors.lastname: Irmler
authors.forename: R
authors.initials: R
authors.lastname: Majdi
authors.forename: A C
authors.initials: AC
authors.lastname: Diserens
authors.forename: A
authors.initials: A
authors.lastname: Fontana
authors.forename: R C
authors.initials: RC
authors.lastname: Janzer
authors.forename: F
authors.initials: F
authors.lastname: Pinet
authors.forename: L
authors.initials: L
authors.lastname: Juillerat-Jeanneret
mesh_terms: D001483:Base Sequence; D001932:Brain Neoplasms / Q000503:physiopathology*; D017931:DNA Primers; D019332:Endothelin-1 / Q000235:genetics / Q000502:physiology*; D053222:Fas Ligand Protein; D005909:Glioblastoma / Q000503:physiopathology*; D006801:Humans; D007150:Immunohistochemistry; D008562:Membrane Glycoproteins / Q000502:physiology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000502:physiology
chemical_list: D017931:DNA Primers; D019332:Endothelin-1; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D019014:fas Receptor